Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Shenogen Pharma of Beijing Raises $20 Million in C Round

publication date: Aug 5, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shenogen Pharma of Beijing raised $20 million in a series C funding, which the company will use to support a Phase II trial of its lead drug candidate, icaritin, a small molecule drug that targets the estrogen receptor alpha 36. The trial will enroll patients with hepatocellular cancer. The drug is derived from barrenwort, a TCM. The funding was led by Legend Capital and Qiming Weichuang Venture Capital. The investors also received warrants to buy an additional $10 million in shares. More details....

Share this with colleagues:

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...